MorphoSys Confident Of A Win Over AbbVie In Myelofibrosis
Phase III Pelabresib Readout Before Year-End
Executive Summary
Sales of the lymphoma drug Monjuvi continue to underwhelm but MorphoSys believes that its investigational BET inhibitor, pelabresib, can become a standard of care for the rare bone marrow disease myelofibrosis.
You may also be interested in...
All Systems Go At Almirall To Enter Tough Atopic Dermatitis Market With Ebglyss
Following a positive opinion from the CHMP, the Spanish company is hoping to launch its challenger to Dupixent in the EU before the end of the year.
First Wave Rises With Sanofi GI Deal
First Wave is licensing Sanofi’s 5-HT4 receptor partial agonist capeserod and is having to pay a mere $500,000 in upfront fees for the privilege.
Pharma Cash Keeps Flowing Into Ireland
MSD and Astellas have joined Lilly, Takeda and AstraZeneca in making major investments in Ireland this year.